Importance of Rebates and Future of Biosimilar Market | AMCP Nexus 2024
An optimistic outlook on the future of the biosimilar market driving down pharmaceutical drug spend.
In this discussion, Javier Gonzalez, Pharm.D., chief growth and commercial officer of Abarca, highlights the critical role of rebates in maintaining affordable health plan premiums and accessibility of specialty drugs.
“A lot of people say that the biosimilar space is at risk - I don't believe that,” Gonzalez said. “I think it will continue to be one of the main drivers of lowering our overall pharmaceutical drug spend over the next five to 10 years.”
Abarca is a health IT company and pharmacy benefit manager. Gonzalez co-led the session, ‘Are Patients Getting a Fair Share of the Value of Biosimilars?’ today at AMCP Nexus, held at the MGM Grand in Las Vegas.
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
